Overview Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19 Status: Not yet recruiting Trial end date: 2020-11-01 Target enrollment: Participant gender: Summary This study compare the efficacy and safety of tocilizumab versus methylprednisolone in the cytokine release syndrome of patients with COVID-19 Phase: Phase 2 Details Lead Sponsor: Hospital Sao DomingosTreatments: MethylprednisoloneMethylprednisolone AcetateMethylprednisolone HemisuccinatePrednisolonePrednisolone acetatePrednisolone hemisuccinatePrednisolone phosphate